Analytical Performance Characteristics of ctDNA MRD Endpoints Working Group

Co-Chairs

Allison Jacob

Vice President, Medical Affairs

Adaptive Biotechnologies

John Simmons, PhD

Global Vice President, Biopharma & Oncology Partnerships

Natera

Mark Sausen, PhD

Senior Director, Precision Medicine Search, Evalutation & Alliance

Bristol Myers Squibb

Current Projects

Drafting an analytical and reporting framework to enable data aggregation across assays, facilitate cross-assay comparisons, and support the evaluation of clinical endpoints.

Participating Organizations

Association for Molecular Pathology (AMP), AstraZeneca, Bristol Myers Squibb (BMS), Exact Sciences, Foresight Diagnostics (Natera), Genentech / Roche, J&J, LGC Group, Lilly, Natera, Novartis, nRichDx, PreAnalytiX, Roche, Thermofisher, University of Arkansas for Medical Sciences, Ultima Genomics, University of Ghent

Past Deliverables

Not applicable at this time.

Meetings

This working group meets on zoom every other Tuesday from 12:00 - 1:00 PM EST.

Special workshops and sessions:

Not applicable at this time.